Literature DB >> 16770069

Mechanisms to explain surfactant responses.

Alan H Jobe1.   

Abstract

Surfactant is now standard of care for infants with respiratory distress syndrome. Surfactant treatments are effective because of complex metabolic interactions between surfactant and the preterm lung. The large treatment dose functions as substrate; it is taken up by the preterm lung and is reprocessed and secreted with improved function. The components of the treatment surfactant remain in the preterm lung for days. If lung injury is avoided, then surfactant inhibition is minimized. Prenatal corticosteroids complement surfactant to further enhance lung function. The magic of surfactant therapy results from the multiple interactions between surfactant and the preterm lung. Copyright (c) 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16770069     DOI: 10.1159/000092866

Source DB:  PubMed          Journal:  Biol Neonate        ISSN: 0006-3126


  8 in total

1.  Assessment of lung ventilation in infants with respiratory distress syndrome using electrical impedance tomography.

Authors:  I Chatziioannidis; T Samaras; G Mitsiakos; P Karagianni; N Nikolaidis
Journal:  Hippokratia       Date:  2013-04       Impact factor: 0.471

2.  NICU bedside caregivers sustain process improvement and decrease incidence of bronchopulmonary dysplasia in infants < 30 weeks gestation.

Authors:  Sara J Mola; David J Annibale; Carol L Wagner; Thomas C Hulsey; Sarah N Taylor
Journal:  Respir Care       Date:  2014-11-25       Impact factor: 2.258

Review 3.  An overview of pulmonary surfactant in the neonate: genetics, metabolism, and the role of surfactant in health and disease.

Authors:  Paul O Nkadi; T Allen Merritt; De-Ann M Pillers
Journal:  Mol Genet Metab       Date:  2009-02-04       Impact factor: 4.797

4.  Macrophage dysfunction and susceptibility to pulmonary Pseudomonas aeruginosa infection in surfactant protein C-deficient mice.

Authors:  Stephan W Glasser; Albert P Senft; Jeffrey A Whitsett; Melissa D Maxfield; Gary F Ross; Theresa R Richardson; Daniel R Prows; Yan Xu; Thomas R Korfhagen
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

Review 5.  Surfactant administration in neonates: A review of delivery methods.

Authors:  Nina Nouraeyan; Alicia Lambrinakos-Raymond; Marisa Leone; Guilherme Sant'Anna
Journal:  Can J Respir Ther       Date:  2014

Review 6.  Beractant and poractant alfa in premature neonates with respiratory distress syndrome: a systematic review of real-world evidence studies and randomized controlled trials.

Authors:  Manuel Sánchez Luna; Peter Bacher; Kristina Unnebrink; Marisol Martinez-Tristani; Cristina Ramos Navarro
Journal:  J Perinatol       Date:  2020-02-12       Impact factor: 2.521

7.  Exogenous pulmonary surfactant in COVID-19 ARDS. The similarities to neonatal RDS suggest a new scenario for an 'old' strategy.

Authors:  Reena M Bhatt; Howard W Clark; Massimo Girardis; Stefano Busani
Journal:  BMJ Open Respir Res       Date:  2021-09

8.  "Optimal surfactant delivery protocol using the bovine lipid extract surfactant: a quality improvement study".

Authors:  Alexandra Germain; Nina Nouraeyan; Martine Claveau; Marisa Leone; Guilherme Sant'Anna
Journal:  J Perinatol       Date:  2020-10-03       Impact factor: 2.521

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.